Research Library — Page 42 | Reta Compare
3563 research articles. Page 42 of 143.
Articles
- FDA and Unapproved New Drug Enforcement
- How FDA Defines 'Essentially a Copy' in Compounding
- The Drug Quality and Security Act at 12 Years
- FDA MedWatch Reports on Compounded GLP-1 Adverse Events
- FDA Import Alert 66-40: What Compounders Should Know
- Counterfeit Semaglutide Seizures in 2025 and 2026
- FDA Policy on Stability Testing for Compounded Peptides
- FDA's Approach to Bulk Drug Substance Nominations
- What Triggers an FDA Inspection of a Compounding Pharmacy
- FDA Enforcement Actions Database: How to Search It
- FDA and State Board Coordination on Compounding
- FDA Warning Letter Language: Reading Between the Lines
- FDA's Stance on Compounded Retatrutide
- The FDA Untitled Letter Explained
- FDA Injunctions Against Compounded Peptide Pharmacies
- FDA Consent Decrees in Compounded GLP-1 Enforcement
- FDA Criminal Referrals for Compounded Drug Violations
- FDA Enforcement Reports: Quarterly Trends in 2026
- FDA's New Office of Compounding Quality
- How FDA Coordinates With DEA on Peptide Matters
- FDA Oversight of Digital Pharmacies and Telehealth
- FDA Rulemaking on Compounded Peptides: What's in Process
- FDA Foreign Inspections of GLP-1 API Manufacturers
- FDA Warning Letters: Compounded Semaglutide Versions
- FDA Actions Against 'Research Peptide' Retailers